News
= LISA News
18.08.2022
Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
11.08.2022
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
10.08.2022
F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim
05.08.2022
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
03.08.2022
QUANTRO Therapeutics kooperiert mit Boehringer Ingelheim in der Entwicklung von Wirkstoffkandidaten zur Transkriptionsregulation
03.08.2022
Erste Jahreshälfte 2022: Boehringer Ingelheim stärkt Forschungspipeline und setzt Wachstum fort
02.08.2022
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine
02.08.2022
Biosynth Carbosynth to offer Enzyme Development following Acquisition of EUCODIS Bioscience